A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
Public ClinicalTrials.gov record NCT01713530. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare the difference in change in glycosylated haemoglobin (HbA1c) between insulin degludec/insulin aspart (IDegAsp) and/or oral anti-diabetic drugs (OADs) and insulin degludec (IDeg) plus insulin aspart (IAsp)and/or OADs.
Study identification
- NCT ID
- NCT01713530
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 274 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2013
- Primary completion
- Jan 8, 2014
- Completion
- Jan 8, 2014
- Last update posted
- Apr 1, 2018
2013 – 2014
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Greenbrae | California | 94904 | — |
| Novo Nordisk Investigational Site | Mission Hills | California | 91345 | — |
| Novo Nordisk Investigational Site | San Diego | California | 92111 | — |
| Novo Nordisk Investigational Site | Kissimmee | Florida | 34741 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60607 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46254 | — |
| Novo Nordisk Investigational Site | Slidell | Louisiana | 70461-4231 | — |
| Novo Nordisk Investigational Site | Rockville | Maryland | 20852 | — |
| Novo Nordisk Investigational Site | Buckley | Michigan | 49620 | — |
| Novo Nordisk Investigational Site | Hillsborough | New Jersey | 08844-1225 | — |
| Novo Nordisk Investigational Site | Lawrenceville | New Jersey | 08648 | — |
| Novo Nordisk Investigational Site | Toms River | New Jersey | 08755-8050 | — |
| Novo Nordisk Investigational Site | Greensboro | North Carolina | 27408 | — |
| Novo Nordisk Investigational Site | Whiteville | North Carolina | 28472 | — |
| Novo Nordisk Investigational Site | Kettering | Ohio | 45429 | — |
| Novo Nordisk Investigational Site | Wadsworth | Ohio | 44281-9236 | — |
| Novo Nordisk Investigational Site | Pittsburgh | Pennsylvania | 15236 | — |
| Novo Nordisk Investigational Site | Kingsport | Tennessee | 37660 | — |
| Novo Nordisk Investigational Site | Austin | Texas | 78731 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75246 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77024 | — |
| Novo Nordisk Investigational Site | Round Rock | Texas | 78681 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78224 | — |
| Novo Nordisk Investigational Site | Tacoma | Washington | 98405 | — |
| Novo Nordisk Investigational Site | Martinsburg | West Virginia | 25401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
Recently updated Diabetes trials
Other public records listing Diabetes. Sorted by last update posted; newest first. Not a recommendation.
- NCT07784127: Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation Not yet recruiting
- NCT07748858: Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities Recruiting
- NCT05561595: Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma Recruiting
- NCT05912647: Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes Recruiting
- NCT07676188: Leveraging Interventions for Needs and Knowledge in Diabetes (LINKD) Not yet recruiting
- NCT07674420: Wearable Insoles for Recurrent Diabetic Ulcer Prevention Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01713530, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2018 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01713530 live on ClinicalTrials.gov.